博济医药2025 年第一次临时股东大会法律意见书 北京市康达（广州）律师事务所 关于博济医药科技股份有限公司 2025 年第一次临时股东大会 法 律 意 见 书 致：博济医药科技股份有限公司 博济医药科技股份有限公司（下称"博济医药"或"公司"） 2025 年第一 次临时股东大会（以下简称"本次股东大会"）于 2025 年 9 月 12 日下午 14 时 30 分在广州市天河区华观路 1933 号万科云广场 A 栋 7 层公司会议室一召开。北 京市康达（广州）律师事务所（以下简称"本所"）受博济医药委托，根据《中 华人民共和国公司法》（下称"《公司法》"）、《中华人民共和国证券法》(下 称"《证券法》")、《上市公司章程指引》（下称"《章程指引》"）、《上 市公司股东大会规则》（下称"《股东大会规则》"）、《深圳证券交易所上市 公司股东大会网络投票实施细则》（下称"《深交所网络投票实施细则》"）等 法律、法规、规范性文件以及《博济医药科技股份有限公司章程》（下称"博济 医药《公司章程》"）的规定，对本次股东大会的召集、召开程序、出席会议人 员资格以及表决方式、表决程序、表决结果等事项进行见证并出具本法律意见书 ...

博济医药科技股份有限公司 第五届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300404 证券简称：博济医药 公告编号：2025-073 经审核，监事会一致认为：公司目前财务状况稳健，为提高公司的资金使用 效率，合理利用暂时闲置资金，在不影响公司正常经营的情况下，公司及子公司 使用暂时闲置自有资金购买安全性高、流动性好、风险可控的理财产品，有利于 提高公司资金的使用效率，不存在损害公司及全体股东，特别是中小股东利益的 情形。该事项决策和审议程序合法、合规。因此，监事会同意公司及子公司使用 不超过 2.5 亿元暂时闲置自有资金进行现金管理。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 三、 备查文件 1、《博济医药科技股份有限公司第五届监事会第十六次会议决议》 特此公告。 博济医药科技股份有限公司监事会 2025 年 9 月 13 日 1 一、 监事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届监事会第十六次会 议于 2025 年 9 月 12 日在公司会议室召开，会议采取现场投票方式对议案 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-072 博济医药科技股份有限公司 第五届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 博济医药科技股份有限公司（以下简称"公司"）第五届董事会第十七次会 议于 2025 年 9 月 12 日在公司会议室召开，会议采取现场结合通讯投票的方式对 议案进行表决。本次会议经全体董事同意豁免提前通知期限要求。会议应到董事 7 人，实到 7 人，会议由董事长王廷春先生主持，部分监事和部分高管列席了本 次董事会。本次董事会的召集、召开符合《公司法》《公司章程》及相关法规的 规定。 2025 年 9 月 13 日 1 二、董事会会议审议情况 1、 审议通过了《关于使用暂时闲置自有资金进行现金管理的议案》 经审议，董事会一致认为：为了提高公司资金使用效率，合理利用暂时闲置 资金，在不影响正常经营的情况下，同意公司及子公司使用额度不超过人民币 2.5 亿元的暂时闲置自有资金购买安全性高、流动性好、风险可控的理财产品， 增加公司收益，在上述额度内，资金可以滚动循环使 ...

Core Viewpoint - Boji Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 23.08% but a recent decline in the short term, indicating potential volatility in the market [1][2]. Financial Performance - As of June 30, Boji Pharmaceutical reported a revenue of 361 million yuan, representing a year-on-year growth of 5.88%. However, the net profit attributable to shareholders decreased by 48.33% to approximately 15.57 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to approximately 27.76 million yuan, with 12.08 million yuan distributed over the past three years [3]. Stock Market Activity - On September 9, Boji Pharmaceutical's stock price fell by 2.01% to 10.73 yuan per share, with a trading volume of approximately 55.94 million yuan and a turnover rate of 1.84%. The total market capitalization stands at 4.14 billion yuan [1]. - The net outflow of main funds was approximately 1.31 million yuan, with large orders buying 7.36 million yuan (13.17%) and selling 8.68 million yuan (15.52%) [1]. Business Overview - Boji Pharmaceutical, established on September 29, 2002, and listed on April 24, 2015, is based in Guangzhou, Guangdong Province. The company specializes in providing preclinical research services, clinical research services, technology transfer services, and other consulting services related to new drug development [1]. - The revenue composition of Boji Pharmaceutical includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from other sources [1].

Core Viewpoint - Boji Pharmaceutical has received approval from the National Medical Products Administration for its clinical trial application of "FCZR" [2] Group 1 - The company announced the approval of its clinical trial for "FCZR" on the evening of September 3 [2] - The approval is a significant step for the company's research and development efforts in the pharmaceutical sector [2]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Core Viewpoint - Boji Pharmaceutical (300404) has received approval from the National Medical Products Administration for its clinical trial application for "FCZR," which is intended for the treatment of ear fungal disease [1] Company Summary - Boji Pharmaceutical announced on September 3 that it has obtained the clinical trial approval notice for "FCZR" from the National Medical Products Administration [1] - The proposed indication for FCZR is ear fungal disease [1]

Group 1 - The company Boji Pharmaceutical (300404.SZ) has received approval from the National Medical Products Administration for the clinical trial of its drug "FCZR" [1] - FCZR is a modified new drug of category 2.2/2.4, optimized based on known active ingredients, with significant clinical advantages, targeting the indication of ear fungal disease [1] - Ear fungal disease is a common infectious condition in otolaryngology, often recurring and difficult to cure, particularly prevalent in hot and humid seasons and regions [1] Group 2 - The formulation of FCZR offers advantages in fluidity and ease of administration, allowing for direct contact with lesions in the ear canal through ear drops, thus achieving localized therapeutic effects [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets, and there are no related sales data available [1]

Core Viewpoint - Boji Pharmaceutical has received approval from the National Medical Products Administration for its clinical trial of the new drug "FCZR," which targets ear fungal infections and offers significant clinical advantages over existing treatments [1] Company Summary - Boji Pharmaceutical (300404.SZ) has announced the approval of its drug "FCZR" for clinical trials, indicating progress in its product development pipeline [1] - The drug is classified as a modified new drug of category 2.2/2.4, optimized for formulation, prescription process, administration route, and indications [1] Industry Summary - Ear fungal disease is a common infectious condition in otolaryngology, particularly prevalent in hot and humid seasons and regions, often recurring and difficult to cure [1] - Currently, there are no approved drugs for this condition in both domestic and international markets, highlighting a potential market opportunity for FCZR [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its drug "FCZR," which is intended for the treatment of ear fungal disease, marking a significant milestone in its new drug development process [1] Group 1: Drug Approval - The drug "FCZR" has been granted a clinical trial approval notice with the registration classification of chemical drug categories 2.2/2.4 [1] - The approval notice numbers are 2025LP02257 and 2025LP02258, indicating the official sanction to commence clinical trials [1] - This type of drug formulation offers advantages in terms of fluidity and ease of administration [1] Group 2: Market Context - Currently, there are no similar drugs approved for market use domestically or internationally, highlighting the uniqueness of "FCZR" [1] - The approval represents a phase of achievement in the company's new drug research and development efforts [1] - The impact of this approval on the company's overall business performance is expected to be minor [1]